Care of patients with non-small-cell lung cancer stage III -
the Central European real-world experience

J 2020

Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience

ZEMANOVA, Milada, Robert PIRKER, Lubos PETRUZELKA, Zuzana ZBOŽÍNKOVÁ, Dragana JOVANOVIC et. al.

Základní údaje

Originální název

Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience

Autoři

ZEMANOVA, Milada (203 Česká republika, garant), Robert PIRKER (40 Rakousko), Lubos PETRUZELKA (203 Česká republika), Zuzana ZBOŽÍNKOVÁ (203 Česká republika, domácí), Dragana JOVANOVIC (688 Srbsko), Mirjana RAJER (705 Slovinsko), Krisztina BOGOS (348 Maďarsko), Gunta PURKALNE (428 Lotyšsko), Vesna CERIMAN (688 Srbsko), Subhash CHAUDHARY (203 Česká republika), Igor RICHTER (203 Česká republika), Jiri KUFA (203 Česká republika), Lenka JAKUBÍKOVÁ (203 Česká republika, domácí), Marius ZEMAITIS (440 Litva), Marketa CERNOVSKA (203 Česká republika), Leona KOUBKOVA (203 Česká republika), Zdenka VILASOVA (203 Česká republika), Karin DIECKMANN (40 Rakousko), Attila FARKAS (348 Maďarsko), Jelena SPASIC (688 Srbsko), Kateřina FRÖHLICH (203 Česká republika, domácí), Andreas TIEFENBACHER (40 Rakousko), Virag HOLLOSI (348 Maďarsko), Juraj KULTAN (203 Česká republika), Iveta KOLAROVA (203 Česká republika) a Jiri VOTRUBA (203 Česká republika)

Vydání

RADIOLOGY AND ONCOLOGY, Ljubljana, Association of Radiology and Oncology, 2020, 1318-2099

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovinsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.991

Kód RIV

RIV/00216224:14110/20:00115905

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2478/raon-2020-0026

UT WoS

000537450400008

Klíčová slova anglicky

diagnostic procedures; multimodality treatment; non-small-cell lung cancer; stage III

Štítky

14110215, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 7. 2020 12:36, Mgr. Tereza Miškechová

Anotace

V originále

Background. Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the realworld setting in Central European countries to define areas for improvements. Patients and methods. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions. The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.

Citovat

ZEMANOVA, Milada, Robert PIRKER, Lubos PETRUZELKA, Zuzana ZBOŽÍNKOVÁ, Dragana JOVANOVIC, Mirjana RAJER, Krisztina BOGOS, Gunta PURKALNE, Vesna CERIMAN, Subhash CHAUDHARY, Igor RICHTER, Jiri KUFA, Lenka JAKUBÍKOVÁ, Marius ZEMAITIS, Marketa CERNOVSKA, Leona KOUBKOVA, Zdenka VILASOVA, Karin DIECKMANN, Attila FARKAS, Jelena SPASIC, Kateřina FRÖHLICH, Andreas TIEFENBACHER, Virag HOLLOSI, Juraj KULTAN, Iveta KOLAROVA a Jiri VOTRUBA. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience. RADIOLOGY AND ONCOLOGY. Ljubljana: Association of Radiology and Oncology, 2020, roč. 54, č. 2, s. 209-220. ISSN 1318-2099. Dostupné z: https://dx.doi.org/10.2478/raon-2020-0026.

@article{1668823,
   author = {Zemanova, Milada and Pirker, Robert and Petruzelka, Lubos and Zbožínková, Zuzana and Jovanovic, Dragana and Rajer, Mirjana and Bogos, Krisztina and Purkalne, Gunta and Ceriman, Vesna and Chaudhary, Subhash and Richter, Igor and Kufa, Jiri and Jakubíková, Lenka and Zemaitis, Marius and Cernovska, Marketa and Koubkova, Leona and Vilasova, Zdenka and Dieckmann, Karin and Farkas, Attila and Spasic, Jelena and Fröhlich, Kateřina and Tiefenbacher, Andreas and Hollosi, Virag and Kultan, Juraj and Kolarova, Iveta and Votruba, Jiri},
   article_location = {Ljubljana},
   article_number = {2},
   doi = {http://dx.doi.org/10.2478/raon-2020-0026},
   keywords = {diagnostic procedures; multimodality treatment; non-small-cell lung cancer; stage III},
   language = {eng},
   issn = {1318-2099},
   journal = {RADIOLOGY AND ONCOLOGY},
   title = {Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience},
   url = {https://www.radioloncol.com/index.php/ro/article/view/3384},
   volume = {54},
   year = {2020}
}

TY  - JOUR
ID  - 1668823
AU  - Zemanova, Milada - Pirker, Robert - Petruzelka, Lubos - Zbožínková, Zuzana - Jovanovic, Dragana - Rajer, Mirjana - Bogos, Krisztina - Purkalne, Gunta - Ceriman, Vesna - Chaudhary, Subhash - Richter, Igor - Kufa, Jiri - Jakubíková, Lenka - Zemaitis, Marius - Cernovska, Marketa - Koubkova, Leona - Vilasova, Zdenka - Dieckmann, Karin - Farkas, Attila - Spasic, Jelena - Fröhlich, Kateřina - Tiefenbacher, Andreas - Hollosi, Virag - Kultan, Juraj - Kolarova, Iveta - Votruba, Jiri
PY  - 2020
TI  - Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience
JF  - RADIOLOGY AND ONCOLOGY
VL  - 54
IS  - 2
SP  - 209-220
EP  - 209-220
PB  - Association of Radiology and Oncology
SN  - 13182099
KW  - diagnostic procedures
KW  - multimodality treatment
KW  - non-small-cell lung cancer
KW  - stage III
UR  - https://www.radioloncol.com/index.php/ro/article/view/3384
L2  - https://www.radioloncol.com/index.php/ro/article/view/3384
N2  - Background. Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the realworld setting in Central European countries to define areas for improvements. Patients and methods. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions. The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.
ER  -

ZEMANOVA, Milada, Robert PIRKER, Lubos PETRUZELKA, Zuzana ZBOŽÍNKOVÁ, Dragana JOVANOVIC, Mirjana RAJER, Krisztina BOGOS, Gunta PURKALNE, Vesna CERIMAN, Subhash CHAUDHARY, Igor RICHTER, Jiri KUFA, Lenka JAKUBÍKOVÁ, Marius ZEMAITIS, Marketa CERNOVSKA, Leona KOUBKOVA, Zdenka VILASOVA, Karin DIECKMANN, Attila FARKAS, Jelena SPASIC, Kateřina FRÖHLICH, Andreas TIEFENBACHER, Virag HOLLOSI, Juraj KULTAN, Iveta KOLAROVA a Jiri VOTRUBA. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience. \textit{RADIOLOGY AND ONCOLOGY}. Ljubljana: Association of Radiology and Oncology, 2020, roč.~54, č.~2, s.~209-220. ISSN~1318-2099. Dostupné z: https://dx.doi.org/10.2478/raon-2020-0026.

Podrobný výpis o publikaci